{"id":5963,"date":"2025-10-23T10:56:30","date_gmt":"2025-10-23T17:56:30","guid":{"rendered":"https:\/\/www.iths.org\/participate\/?p=5963"},"modified":"2025-10-23T11:02:51","modified_gmt":"2025-10-23T18:02:51","slug":"tibushield-hs-study","status":"publish","type":"post","link":"https:\/\/www.iths.org\/participate\/tibushield-hs-study\/","title":{"rendered":"TibuSHIELD HS Study"},"content":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text css=””]<\/p>\n

Study Description<\/h3>\n

The purpose of this study is to evaluate the effect of tibulizumab in adults with Hidradenitis Suppurativa.<\/p>\n

Tibulizumab is an experimental drug, which means it has not been approved by the Food and Drug Administration (FDA). This means the safety and effectiveness of this experimental drug is still being studied.<\/p>\n

Participation will start with a 30-day screening period, followed by 16 weeks of taking tibulizumab or placebo twice in the first month, then once a month after; followed by a 16-week period of taking tibulizumab once a month. There will be an 8-week time period to follow-up for safety. During these visits participants may have a physical exam, blood draw, have skin examined for lesions and those present counted, and asked to fill out a diary, questionnaires and surveys. Participants will receive compensation for taking part in the study and reimbursement for travel.<\/p>\n

Participant Eligibility<\/h3>\n

\u2022 Be at least 18 years old
\n\u2022 Your HS has not gotten better with antibiotic treatment, or you are unable to use antibiotics to treat your HS.
\n\u2022 No prior use of a medicine called secukinumab, ixekizumab, or bimekizumab<\/p>\n

Contact<\/h3>\n

Camila Marquez
\n(206) 543-5312<\/p>\n

\n

Additional Study Details<\/h3>\n

Full Study Title<\/strong>
\nA Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Hidradenitis Suppurativa (TibuSHIELD)
\n<\/span><\/p>\n

Study ID:<\/strong> SSU00296084<\/div>\n
ClinicalTrials.gov Link:<\/strong> NCT06959225<\/a><\/div>\n
<\/div>\n
Start Date:<\/strong> 08\/26\/2025<\/div>\n
End Date:<\/strong> 10\/31\/2027<\/div>\n
<\/div>\n

Investigator(s)<\/strong>
\nDr. Vivian Shi
\n<\/span>
\nAccepts Healthy Volunteers?<\/strong>
\nNo<\/span><\/p>\n

Study Site(s)<\/strong><\/p>\n

\n

University of Washington<\/h4>\n

1959 NE Pacific St.
\nSeattle, Washington 98195<\/p>\n<\/div>\n

\n

<\/h4>\n<\/div>\n
<\/div>\n

<\/div>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text css=””] Study Description The purpose of this study is to evaluate the effect of tibulizumab in adults with Hidradenitis Suppurativa. Tibulizumab is an experimental drug, which means it has not been approved by the Food and Drug…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[1694,1203,1692,1693],"class_list":["post-5963","post","type-post","status-publish","format-standard","hentry","category-skin-hair-and-nails","tag-acne-inversa","tag-adult","tag-dermatology","tag-hidradenitis-suppurativa"],"_links":{"self":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/comments?post=5963"}],"version-history":[{"count":4,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5963\/revisions"}],"predecessor-version":[{"id":5967,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/posts\/5963\/revisions\/5967"}],"wp:attachment":[{"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/media?parent=5963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/categories?post=5963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iths.org\/participate\/wp-json\/wp\/v2\/tags?post=5963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}